Lower-than-expected volume growth and higher-than-expected combined ratio have set up a weak H1FY24 for Star Health (Star). The balance between premium price hike and tighter underwriting, leading to optimal volume growth and combined ratio, would be key in setting the trajectory back to the long-term targets of 20% RoE, 20% growth with 200% solvency.